 | BT Pharma Headquarters and Laboratories Prologue-Biotech Rue Pierre et Marie Curie BP 28262 31682 Labège-Innopole Cedex France Tel.: +33 (0)5 61 28 70 60 Fax: +33 (0)5 61 28 70 69 Email: business@btpharma.com Website: http://www.btpharma.com/ |
BT PHARMA is an emerging biopharmaceutical company focused on developing innovative therapeutic vaccines caused by human papillomavirus (HPV) for the treatment of cervical cancer and associated neoplasia. The company's lead candidate therapeutic vaccine, ProCervix® is scheduled to receive approval for its first clinical trials in 2009. BT PHARMA plans to develop ProCervix® to proof of concept stage.
The company was created in October 2001 and is based in Labège (Toulouse), France.
Corporate Profile
BT PHARMA is an emerging biopharmaceutical company focused on developing innovative therapeutic vaccines for the treatment of cervical cancer and associated neoplasia.
Cervical cancer and associated neoplasia are a major healthcare problem. They are the result of infection by the Human Papillomavirus (HPV) and are one of the most common sexually transmitted diseases affecting women.
BT PHARMA’s lead candidate therapeutic vaccine, ProCervix® is scheduled to receive approval for its first clinical trials in 2009. ProCervix® is based on BT PHARMA’s unique CyaA vector system which is able to deliver the appropriate HPV antigens needed to induce strong and specific T cell responses. BT PHARMA plans to develop ProCervix® to proof of concept stage. The company then intends to work with an appropriate partner to further develop and commercialize this exciting new therapeutic vaccine product.
In addition, BT PHARMA has a number of other therapeutic vaccine development programs based on its CyaA vector system. These are TAAVAC, for Tumour Associated Antigen Vaccine for a range of human cancers, and DOGTAA, which targets many cancers in companion animals.
Finally, the company also has a second vaccine vector called PepTel® which uniquely has intrinsic adjuvant ability. This promising technology platform is available for licensing.
BT PHARMA is managed by a team of experienced biotech professionals and has developed a strong network of collaborators. The company continues to work with scientists, at Institut Pasteur, who are the world leading experts in the CyaA vector technology. The company also works with leading clinicians with significant experience in conducting clinical trials with cervical cancer vaccines.
BT PHARMA started operations in October 2001 following its spin off from the Institut Pasteur. The company is headquartered in state-of-the-art facilities in Labège (Toulouse), France and employs 18 people.
Source: BT Pharma
